12 Best Low Price Pharma Stocks To Invest In Right Now

Page 4 of 10

7. Viatris Inc. (NASDAQ:VTRS)

Share Price as of the Close of February 21: $11.25

Viatris Inc. (NASDAQ:VTRS) is a Pennsylvania-based pharmaceutical company that specializes in a wide variety of therapeutic areas.  In 2020, the business separated from Pfizer. It is currently going through a phase of strong worldwide execution, which is causing its core business to rise steadily. This trend is anticipated to continue into the upcoming year. $133 million of its $3.8 billion in total revenues came from new goods. Additionally, by paying off almost $1.9 billion in debt, the company improved its financial standing. It also broadened its intellectual portfolio by entering into an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin outside of the US and Europe.

Viatris Inc. (NASDAQ:VTRS) is well-positioned to produce consistent growth in its core business, invest in its operations, and return a significant amount of capital to shareholders because of its sector-leading cash flow and strong balance sheet. The company’s operating cash flow in the most recent quarter was $826.5 million, while its free cash flow was almost $750 million.

Despite efforts to lower its debt in the most recent quarter, Viatris Inc. (NASDAQ:VTRS) still owes more than $16 billion. Although this might worry some investors, it might not be a big deal considering the company’s dedication to giving shareholders their money back. Viatris Inc. (NASDAQ:VTRS) pays out about $580 million in dividends every year, suggesting that its current payout is probably sustainable. Since 2021, the business has been giving stockholders dividends regularly. As of February 20, it has a dividend yield of 4.25% and pays out a $0.12 quarterly dividend per share.

Viatris Inc. (NASDAQ:VTRS) remained popular among elite funds in Q4 2024, with 48 funds tracked by Insider Monkey owning positions in the company, up from 57 in the previous quarter.

Page 4 of 10